Goldsmith M, Koutcher JA, Damadian R (1978) NMR in cancer, XIII: application of the NMR malignancy index to human mammary tumours. Br J Cancer 38:547–554. https://doi.org/10.1038/bjc.1978.243
Article CAS PubMed PubMed Central Google Scholar
Ross RJ, Thompson JS, Kim K, Bailey RA (1982) Nuclear magnetic resonance imaging and evaluation of human breast tissue: preliminary clinical trials. Radiology 143:195–205. https://doi.org/10.1148/radiology.143.1.7063727
Article CAS PubMed Google Scholar
el Yousef S, O’Connell D, Duchesneau R et al (1985) Benign and malignant breast disease: magnetic resonance and radiofrequency pulse sequences. AJR Am J Roentgenol 145:1–8. https://doi.org/10.2214/ajr.145.1.1
Heywang S, Fenzl G, Edmaier M et al (1985) Kernspintomographie in der Mammadiagnostik. Rofo 143:207–212. https://doi.org/10.1055/s-2008-1052791
Heywang SH, Hahn D, Schmidt H et al (1986) MR Imaging of the Breast Using Gadolinium-DTPA. J Comput Assist Tomogr 10:199–204. https://doi.org/10.1097/00004728-198603000-00005
Article CAS PubMed Google Scholar
Kaiser WA, Zeitler E (1989) MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology 170:681–686. https://doi.org/10.1148/radiology.170.3.2916021
Article CAS PubMed Google Scholar
Sardanelli F, Podo F (2020) From NMR to Clinical Breast MRI. Breast MRI for High-risk Screening. Springer International Publishing, Cham, pp 1–9
Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1. Science (80- ) 266:66–71. https://doi.org/10.1126/science.7545954
Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792. https://doi.org/10.1038/378789a0
Article CAS PubMed Google Scholar
National Collaborating Centre for Primary Care (UK), National Collaborating Centre for Primary Care (2006) Familial breast cancer.The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care Update, July 2006 National Collaborating Centre for Primary Royal College of General Practitioners London
Saslow D, Boetes C, Burke W et al (2007) American cancer society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89. https://doi.org/10.3322/canjclin.57.2.75
Selamoglu A, Gilbert FJ (2020) Guidelines and Recommendations on High-Risk Breast Cancer Screening All Over the World: Agreements and Differences. Breast MRI for High-risk Screening. Springer International Publishing, Cham, pp 251–267
MRI for high risk women |Updated Medicare information for funding of MRI scans for women under 50 at high risk of breast cancer. https://www.canceraustralia.gov.au/clinical-best-practice/breast-cancer/screening-and-early-detection/mri-high-risk-women. Accessed 18 Nov 2023
Daly MB, Pal T, Berry MP et al (2021) Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 19:77–102. https://doi.org/10.6004/jnccn.2021.0001
Singer CF, Tea MK, Pristauz G et al (2015) Clinical Practice Guideline for the prevention and early detection of breast and ovarian cancer in women from HBOC (hereditary breast and ovarian cancer) families. Wien Klin Wochenschr 127:981–986. https://doi.org/10.1007/s00508-015-0880-x
Article CAS PubMed Google Scholar
Bick U, Engel C, Krug B et al (2019) High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. Breast Cancer Res Treat 175:217–228. https://doi.org/10.1007/s10549-019-05152-9
Biganzoli L, Calabrese M, Conte B, et al (2018) AIOM Breast neoplasms guidelines. Available via https://www.aiom.it/linee-guida-aiom-2018-neoplasie-della-mammella-11/
Llort G, Chirivella I, Morales R et al (2015) SEOM clinical guidelines in hereditary breast and ovarian cancer. Clin Transl Oncol 17:956–961. https://doi.org/10.1007/s12094-015-1435-3
Article CAS PubMed PubMed Central Google Scholar
The Israel Cancer Association – Breast Cancer. https://en.cancer.org.il/template_e/default.aspx?PageId=7749
Bart G, Frans G, Guido VH, et al (2016) Richtlijnen – BORSTKANKERSCREENING. Antwerpen
Ontario Breast Screening Program Screening for Women at High Risk – Cancer Care Ontario. https://www.cancercareontario.ca/en/guidelinesadvice/cancer-continuum/screening/breast-cancer-high-risk
Tjelle TE, Einar T, Movik E et al (2018) Diagnostic accuracy, clinical effectiveness and budget impact of screening BRCA1/2 mutation carriers by MRI. A health technology assessment, Oslo. Available via https://www.fhi.no/en/publ/2018/Diagnostic-accuracy-clinical-effectiveness-and-budget-impact-of-screening-BRCA1-2-mutation-carriers-by-MRI/
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. London: National Institute for Health and Care Excellence (NICE) https://pubmed.ncbi.nlm.nih.gov/31940157/
Jaeschke R (1994) Users’ guides to the medical literature. III. How to use an article about a diagnostic test. B. what are the results and will they help me in caring for my patients? the evidence-based medicine working group. JAMA 271:703–707. https://doi.org/10.1001/jama.271.9.703
Irwig L, Houssami N, Armstrong B, Glasziou P (2006) Evaluating new screening tests for breast cancer. BMJ 332:678–679. https://doi.org/10.1136/bmj.332.7543.678
Article PubMed PubMed Central Google Scholar
Zackrisson S, Andersson I, Janzon L et al (2006) Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study. BMJ 332:689–692. https://doi.org/10.1136/bmj.38764.572569.7C
Article PubMed PubMed Central Google Scholar
Bakker MF, de Lange SV, Pijnappel RM et al (2019) Supplemental MRI screening for women with extremely dense breast tissue. N Engl J Med 381:2091–2102. https://doi.org/10.1056/NEJMoa1903986
D’Orsi CJ, Sickles EA, Mendelson EB, Morris EA (2013) ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System, 5th edn. American College of Radiology, Reston, VA, USA
Mann RM, Athanasiou A, Baltzer PAT et al (2022) Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI). Eur Radiol 32:4036–4045. https://doi.org/10.1007/s00330-022-08617-6
Article PubMed PubMed Central Google Scholar
Raat HPJ, Lobbes MBI, Veldhuis WB (2021) [Are The Netherlands ready for personalized breast cancer screening? Abbreviated breast MRI and contrast-enhanced mammography for screening in women with dense breasts]. Ned Tijdschr Geneeskd 165.
Gray JAM (1998) The first report of the national screening committee. J Med Screen 5:169–169. https://doi.org/10.1136/jms.5.4.169
Article CAS PubMed Google Scholar
World Health Organization, Regional Office for Europe (2020) Screening programmes: a short guide. Increase effectiveness, maximize benefits and minimize harm. Available via https://iris.who.int/handle/10665/330829
Gilbert R (2001) Assessing diagnostic and screening tests: Part 1 Concepts. West J Med 174:405–409. https://doi.org/10.1136/ewjm.174.6.405
Article CAS PubMed PubMed Central Google Scholar
Dickinson JA, Pimlott N, Grad R et al (2018) Screening: when things go wrong. Can Fam Physician 64:502–508
PubMed PubMed Central Google Scholar
Rasmussen JF, Siersma V, Malmqvist J, Brodersen J (2020) Psychosocial consequences of false positives in the Danish Lung Cancer CT screening trial: a nested matched cohort study. BMJ Open 10:e034682. https://doi.org/10.1136/bmjopen-2019-034682
Article PubMed PubMed Central Google Scholar
Brodersen J, Siersma VD (2013) Long-term psychosocial consequences of false-positive screening mammography. Ann Fam Med 11:106–115. https://doi.org/10.1370/afm.1466
Article PubMed PubMed Central Google Scholar
Lafata JE, Simpkins J, Lamerato L et al (2004) The economic impact of false-positive cancer screens. Cancer Epidemiol Biomarkers Prev 13:2126–32. https://doi.org/10.1158/1055-9965.2126.13.12
Welch HG, Black WC (2010) Overdiagnosis in cancer. J Natl Cancer Inst 102:605–613. https://doi.org/10.1093/jnci/djq099
Sardanelli F, Trimboli RM, Tot T (2018) Expert review of breast pathology in borderline lesions. JAMA Oncol 4:1325–26. https://doi.org/10.1001/jamaoncol.2018.1953
Jenniskens K, de Groot JAH, Reitsma JB et al (2017) Overdiagnosis across medical disciplines: a scoping review. BMJ Open 7:e018448. https://doi.org/10.1136/bmjopen-2017-018448
Article PubMed PubMed Central Google Scholar
McCaffery KJ, Jacklyn GL, Barratt A et al (2015) Recommendations About Screening. In: Guyatt G, Rennie D, Meade MO, Cook DJ (eds) Users’ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd edn. McGraw-Hill Education, New York, NY
Council of the European Union (2022) Council Recommendation on strengthening prevention through early detection: A new EU approach on cancer screening replacing Council Recommendation 2003/878/EC. https://data.consilium.europa.eu/doc/document/ST-14770-2022-INIT/en/pdf
Carter JL, Coletti RJ, Harris RP (2015) Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods. BMJ 350:g7773–g7773. https://doi.org/10.1136/bmj.g7773
Article PubMed PubMed Central Google Scholar
Lawrence G, Wallis M, Allgood P et al (2009) Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias. Breast Cancer Res Treat 116:179–185. https://doi.org/10.1007/s10549-008-0100-8
Mahnken JD, Chan W, Freeman DH, Freeman JL (2008) Reducing the effects of lead-time bias, length bias and over-detection in evaluating screening mammography: a censored bivariate data approach. Stat Methods Med Res 17:643–663. https://doi.org/10.1177/0962280207087309
留言 (0)